Mission BioCapital: From a Copenhagen base to Investment in Danish Biotech
A local presence can help international life science investors connect with emerging companies, research environments and potential investment partners. For US venture capital firm Mission BioCapital, Copenhagen provides a base for developing these relationships across Denmark and Europe.
In 2025, the firm opened its first European office at BioInnovation Institute (BII), with Partner Robert Blazej relocating to Denmark to launch its European office, strengthen relationships with Denmark’s life sciences ecosystem, and identify promising investment opportunities. The location placed Mission BioCapital within a community of emerging biotech companies, alongside a new incubator partnership with BII.
In September 2026, Mission BioCapital co-led a €67.5 million Series A funding round in Danish clinical-stage biotech company Breye Therapeutics alongside Novo Holdings. The funding will support the advancement of Breye’s lead candidate, danegaptide, into Phase II clinical trial for non-proliferative diabetic retinopathy.
ABOUT MISSION BIOCAPITAL
Mission BioCapital is a global venture capital firm focused on building and investing in early-stage life science companies. With offices in Cambridge, San Francisco, Toronto, and Copenhagen, it combines capital with practical support, access to laboratory facilities and strategic partnerships to help founders develop scientific discoveries into businesses.
WHY DENMARK ?
Denmark’s Life Science Strategy towards 2030 reflects a strong commitment to research, investment and sector growth. For international investors and venture capital firms, Denmark offers access to a closely connected life science ecosystem. Its research institutions, companies and support organizations provide opportunities to identify emerging technologies, connect with founders and collaborate on venture creation.
- An established life science cluster spanning biotech, pharmaceuticals, medtech and health tech
- Collaboration between universities, hospitals, investors and industry
- Scientific and entrepreneurial talent
- Support for venture creation and commercialization
- A stable and transparent business environment
- World-class research and health data infrastructure
Mission BioCapital’s Copenhagen office and investment in Breye Therapeutics illustrate how an international investor can build a local presence and participate in the development of Danish biotech companies.
Denmark offers a uniquely integrated ecosystem that allows us to efficiently identify, evaluate, and invest in innovative biotech companies alongside other expert investors, all working together to drive breakthrough science to patients faster. This shared vision and welcoming environment has made for a successful expansion into Denmark, with investments in two BII resident companies already. We are also excited to welcome new team member, Josephine Brysting, Ph.D., to Copenhagen. Josephine is an essential component of Mission BioCapital’s strategy and presence in the region.
Robert Blazej
Ph.D., Partner, Mission BioCapital
Mission BioCapital’s expansion into Denmark reinforces the country’s position as a leading European hub for life science venture creation. It highlights strong international confidence in Denmark’s innovation ecosystem and provides a compelling model for companies looking to establish a European presence.
Ulrik Eversbusch
Director, Invest in Denmark
